title: Effects of alfacalcidol on mechanical properties and collagen cross-links of the femoral diaphysis in glucocorticoid-treated rats.
abstract: Bone fragility is increased in glucocorticoid (GC)-induced osteopenia even though GC-treated patients have higher bone mineral density (BMD), suggesting that the impaired bone quality may affect bone strength. This study was conducted to clarify the effects of GC on bone strength and collagen cross-links of adult rats and the effect of coadministration of alfacalcidol (ALF), a prodrug of active vitamin D(3). Six-month-old male Wistar-Imamichi rats (n = 32) were divided into the following four groups with equal average body weight: (1) 4-week age-matched controls, (2) 4-week GC (prednisolone, 10 mg/kg daily, i.m.) with concomitant administration of vehicle, (3) 4-week GC with concomitant administration of ALF (0.05 μg/kg daily, p.o.), and (4) 4-week GC with concomitant administration of ALF (0.1 μg/kg daily, p.o.). At the end of treatment, BMD, collagen cross-links, mechanical properties of the femoral midshaft, bone metabolic markers, and biochemical parameters were analyzed. In the GC group, femoral bone strength decreased without any change of BMD. This was accompanied by a decrease in the content of enzymatic cross-links. ALF (0.1 μg/kg) inhibited the GC-induced reduction in bone strength. The content of mature cross-links in the 0.1-μg/kg ALF group was significantly higher than that in the GC group. GC treatment caused a decrease in bone metabolic markers and serum calcium levels, which was counteracted by ALF coadministration. Preventive treatment with ALF inhibited the deterioration of bone mechanical properties primarily in association with the restoration of enzymatic cross-link formation and amelioration of the adverse effects of GC treatment on calcium metabolism.
authors.affiliation: Department of Orthopedic Surgery, Jikei University School of Medicine, 3-25-8, Nishi-Skinbaski, Minato-ku, Tokyo 105-8461, Japan. xlink67@gol.com
authors.forename: Mitsuru
authors.initials: M
authors.lastname: Saito
authors.forename: Keishi
authors.initials: K
authors.lastname: Marumo
authors.forename: Chikara
authors.initials: C
authors.lastname: Ushiku
authors.forename: Soki
authors.initials: S
authors.lastname: Kato
authors.forename: Sadaoki
authors.initials: S
authors.lastname: Sakai
authors.forename: Naohiko
authors.initials: N
authors.lastname: Hayakawa
authors.forename: Masahiko
authors.initials: M
authors.lastname: Mihara
authors.forename: Ayako
authors.initials: A
authors.lastname: Shiraishi
mesh_terms: D000818:Animals; D001835:Body Weight; D015519:Bone Density; D050071:Bone Density Conservation Agents / Q000494:pharmacology*; D001842:Bone and Bones / Q000378:metabolism; D003094:Collagen / Q000737:chemistry*; D003432:Cross-Linking Reagents / Q000494:pharmacology; D018483:Diaphyses / Q000187:drug effects*; D005269:Femur / Q000187:drug effects*; D005938:Glucocorticoids / Q000494:pharmacology*; D006887:Hydroxycholecalciferols / Q000494:pharmacology*; D008297:Male; D010024:Osteoporosis / Q000188:drug therapy; D011239:Prednisolone / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D013314:Stress, Mechanical
chemical_list: D050071:Bone Density Conservation Agents; D003432:Cross-Linking Reagents; D005938:Glucocorticoids; D006887:Hydroxycholecalciferols; D003094:Collagen; D011239:Prednisolone; C008088:alfacalcidol